JP
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Application Note
Optimization of complement-dependent cytotoxicity assay on OncoSignature cell lines
Screening candidate mAbs for complement-dependent cytotoxicity (CDC) activity represents a crucial step in the development pipeline of successful therapeutics.
In this application note, we present how our complement-dependent cytotoxicity (CDC) assay offering can help drug screening efforts by leveraging our semi-automated screening platform and OncoSignature™ cell panel.
For research use only. Not for use in diagnostic procedures.
To view the full content please answer a few questions
Download Resource
Optimization of complement-dependent cytotoxicity assay on OncoSignature cell lines